New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Executive Summary
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.
You may also be interested in...
ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price
Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.
Aimovig Priced ‘Well Below’ Part D Specialty Threshold To Avoid Coinsurance
Amgen-Novartis pricing strategy seeks to ensure patients are subject to flat copays rather than coinsurance, which is calculated as a percentage of drug's list price.
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.